Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)
Descrição
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://d3i71xaburhd42.cloudfront.net/cbe394da8b9c9a86472f153dcef8a721a379fb0b/2-Figure1-1.png)
PDF] MGAT2, a Monoacylglycerol Acyltransferase Expressed in the
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11901-020-00533-x/MediaObjects/11901_2020_533_Fig1_HTML.png)
Metabolic Targets in Nonalcoholic Steatohepatitis: Treating the
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://journals.physiology.org/cms/10.1152/ajpendo.90949.2008/asset/images/medium/zh10030955860001.jpeg)
Beyond triglyceride synthesis: the dynamic functional roles of
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-08946-y/MediaObjects/41598_2022_8946_Fig1_HTML.png)
The monoacylglycerol acyltransferase pathway contributes to
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://febs.onlinelibrary.wiley.com/cms/asset/14f5bdcd-8e17-49ef-a74a-b3da54d701a6/feb412778-fig-0002-m.jpg)
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs12276-023-01036-7/MediaObjects/12276_2023_1036_Fig1_HTML.png)
Ablation of the deubiquitinase USP15 ameliorates nonalcoholic
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://chemistry-europe.onlinelibrary.wiley.com/cms/asset/50725939-a041-4317-90db-6c8034422bd1/mcontent.gif)
Therapeutic Strategies for Metabolic Diseases: Small‐Molecule
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://www.ncbi.nlm.nih.gov/books/NBK544043/bin/diab_nonalc_fattyliv-Image002.jpg)
Nonalcoholic Fatty Liver Disease: The Overlooked Complication of
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://febs.onlinelibrary.wiley.com/cms/asset/fed9129d-ce86-4ad8-ae57-3c5551ddaa80/feb412778-fig-0001-m.jpg)
Inhibition of MGAT2 modulates fat‐induced gut peptide release and
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://www.frontiersin.org/files/Articles/1097835/fphar-14-1097835-HTML/image_m/fphar-14-1097835-g001.jpg)
Frontiers New insights into the role of dietary triglyceride
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://ars.els-cdn.com/content/image/1-s2.0-S1550413122004582-gr3.jpg)
MGAT2 inhibitor decreases liver fibrosis and inflammation in
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12986-023-00748-x/MediaObjects/12986_2023_748_Fig3_HTML.png)
Pharmacotherapies of NAFLD: updated opportunities based on
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-022-01119-3/MediaObjects/41392_2022_1119_Fig2_HTML.png)
Targeted therapeutics and novel signaling pathways in non-alcohol
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://publinestorage.blob.core.windows.net/0795e5c9-84ca-453b-b92e-d9d2a5e45d9c/jcth-9-051-g001.jpg)
New Drugs on the Block—Emerging Treatments for Nonalcoholic
![Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH)](https://patentimages.storage.googleapis.com/81/cd/8b/ea5f1c5aec8ed7/US09701672-20170711-C00094.png)
US9701672B2 - Dihydropyridinone MGAT2 inhibitors for use in the
de
por adulto (o preço varia de acordo com o tamanho do grupo)